IRIS - Res&Arch Institutional Research Information System - Research & Archive

Roila, Fausto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.276
AS - Asia 1.900
EU - Europa 1.587
SA - Sud America 480
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
AN - Antartide 1
Totale 6.289
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.195
SG - Singapore 1.010
IE - Irlanda 468
BR - Brasile 410
HK - Hong Kong 346
IT - Italia 317
CN - Cina 248
RU - Federazione Russa 227
VN - Vietnam 121
FR - Francia 117
DE - Germania 106
UA - Ucraina 71
SE - Svezia 63
FI - Finlandia 52
GB - Regno Unito 50
KR - Corea 37
CA - Canada 36
MX - Messico 28
IN - India 27
AR - Argentina 26
AT - Austria 24
NL - Olanda 19
ES - Italia 18
TR - Turchia 18
PL - Polonia 17
BE - Belgio 16
EC - Ecuador 15
IQ - Iraq 14
JP - Giappone 13
ZA - Sudafrica 13
BD - Bangladesh 12
ID - Indonesia 10
PY - Paraguay 9
CO - Colombia 8
PK - Pakistan 7
MA - Marocco 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
JM - Giamaica 5
SA - Arabia Saudita 5
CL - Cile 4
LT - Lituania 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HN - Honduras 3
JO - Giordania 3
KZ - Kazakistan 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
TN - Tunisia 3
UY - Uruguay 3
UZ - Uzbekistan 3
AL - Albania 2
AZ - Azerbaigian 2
GE - Georgia 2
GH - Ghana 2
KE - Kenya 2
NP - Nepal 2
SN - Senegal 2
AD - Andorra 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DJ - Gibuti 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
IS - Islanda 1
LY - Libia 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
PW - Palau 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 6.289
Salva come PNG Salva come JPEG
Città #
Singapore 613
Dublin 468
Chandler 347
Hong Kong 345
Boardman 162
Santa Clara 151
Altamura 135
Princeton 130
Medford 127
Lawrence 124
Moscow 118
Ashburn 116
Los Angeles 75
Perugia 55
Ho Chi Minh City 49
São Paulo 48
New York 44
Beijing 37
Seoul 37
The Dalles 36
Jacksonville 35
San Mateo 33
Munich 29
Helsinki 26
Redmond 26
Andover 25
Ann Arbor 25
Nuremberg 21
Hanoi 20
San Paolo di Civitate 20
Dallas 18
Brussels 16
Piscataway 16
Rome 16
Warsaw 16
Wilmington 16
Shanghai 15
Brooklyn 14
Chicago 14
Houston 14
Frankfurt am Main 13
Montreal 13
Rio de Janeiro 12
Chennai 11
Columbus 11
Napoli 11
San Francisco 11
Tokyo 11
Amsterdam 10
Brasília 10
Denver 10
Falkenstein 10
Stockholm 10
Toronto 10
Turku 10
Guayaquil 9
Ankara 8
Boston 8
Boydton 8
London 8
Mexico City 8
Atlanta 7
Bologna 7
Guangzhou 7
Huskvarna 7
Johannesburg 7
Norwalk 7
Vienna 7
Baghdad 6
Belo Horizonte 6
Des Moines 6
Milan 6
Poplar 6
Porto Alegre 6
Tianjin 6
Woodbridge 6
Charlotte 5
Haiphong 5
Istanbul 5
Lappeenranta 5
Manchester 5
Phoenix 5
Recife 5
Seattle 5
São José dos Campos 5
Wuhan 5
Asunción 4
Bexley 4
Buenos Aires 4
Campinas 4
Changsha 4
Cincinnati 4
Contagem 4
Curitiba 4
Erbil 4
Hefei 4
Kingston 4
Lahore 4
New Delhi 4
Paris 4
Totale 4.047
Salva come PNG Salva come JPEG
Nome #
Primitive thyroid lymphomas 120
Supportive care in cancer—a MASCC perspective 108
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 102
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 96
Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. Case report and review of the literature 95
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 93
High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) responsive to weekly paclitaxel (P) and trastuzumab (T) treatment. 5 National Congress of Medical Oncology, Rome, 21-24 October 2003. 89
Linee guida per la gestione dei pazienti affetti da melanoma cutaneo 88
Surgical treatment of primitive thyroid lymphoma 82
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 81
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 79
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 78
Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature. 76
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 74
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy 71
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines 71
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study 69
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. 68
NICSO: Network Italiano Cure di Supporto in Oncologia – Italian Network for Supportive Care in Oncology 68
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy 67
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 67
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment 67
Raccomandazioni cliniche per il melanoma cutaneo 66
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 65
Incidence, characteristics and treatment of fatigue in oncological cancer patients (PTS) in Italy: A cross-sectional study. 63
Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study 61
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 61
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 61
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 60
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 60
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study 59
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting 58
Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A plus C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study 58
Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients 57
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients 57
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 57
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 57
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 57
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study 56
Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program 55
Acute emesis: moderately emetogenic chemotherapy 55
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 54
Optimal Management of Fatigue 54
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 53
Prevalence and spectrum of brca germline variants in central Italian high risk or familial breast/ovarian cancer patients: A monocentric study 53
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference 53
Targeted therapy for advanced cutaneous melanoma 51
Juvenile papillomatosis of the breast in young male: a case report 51
Prevention and treatment of pandemic influenza in cancer patients. 50
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 50
State of the art of antiemetic therapy 50
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 50
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis 49
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 48
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 48
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 48
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 47
New antiemetic drugs 47
A new payment-by-results method for determining the fair price of new oncological drugs 46
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 46
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron? Reply 46
DOACs in patients with brain cancers: promising but still a long way to go 45
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 45
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case 45
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy 45
Hepatitis B in immunosuppressed cancer patients:pathogenesis, incidence and prophylaxis 44
Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy: a cross-section study 44
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients 44
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 43
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study 43
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference 43
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 41
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 40
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 40
Management of febrile neutropenia: ESMO Clinical Recommendations 38
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis 37
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 37
Chemotherapy-induced nausea and vomiting 37
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the programma Ricerca e Innovazione Emilia Romagna oncology research group 37
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 37
The cost of chemotherapy-induced nausea and vomiting in Italy 36
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life 36
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review 36
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 36
Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines 35
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE 35
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO) 35
Conflict of interest among Italian medical oncologists: A national survey 35
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 35
Management of cancer pain: ESMO Clinical Practice Guidelines 35
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 34
Palonosetron (PALO) plus dexamethasone (DEX) administered on day only prevents emesis and avoids prolonged DEX use in breast cancer patients treated with anthracycline/cyclophosphamide regimens 34
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines 34
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management 33
Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations 33
Update on anticancer drugs 33
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines 33
Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study 32
Daily challenges in oncology practice. What do we need to know about antiemetics? 32
Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use 32
Totale 5.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202172 0 0 0 0 0 8 10 1 23 10 16 4
2021/2022522 3 29 6 11 7 2 4 160 8 24 21 247
2022/20231.478 150 371 32 57 105 78 0 53 557 9 45 21
2023/2024585 28 47 25 14 10 2 128 13 39 40 107 132
2024/20251.771 9 165 27 63 198 74 50 147 470 116 268 184
2025/20261.849 306 230 263 462 495 93 0 0 0 0 0 0
Totale 6.457